Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05583955 · ClinicalTrials.gov registry record · Phase 2
A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)
A Phase 2 study, sponsored by Noema Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT05583955 is a Phase 2 study that has completed, run by Noema Pharma. The registered enrollment target is 75 participants.
The verdict
NCT05583955, a Phase 2 study, has completed, sponsored by Noema Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
This study is designed to evaluate the effectiveness of NOE-105 on speech fluency without the known antipsychotic-induced side effects of commonly used treatments for childhood onset fluency disorder (COFD).
Interventions
- DRUG Placebo
- DRUG NOE-105
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2023-11-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05583955
The ClinicalTrials.gov registry entry for NCT05583955 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noema Pharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05583955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05583955 about?
NCT05583955 is a clinical study titled "A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)". This study is designed to evaluate the effectiveness of NOE-105 on speech fluency without the known antipsychotic-induced side effects of commonly used treatments for childhood onset fluency disorder (COFD).
What is the current status of trial NCT05583955?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2022-07-25. Estimated completion is 2023-11-24.
What interventions are being tested in trial NCT05583955?
The interventions under investigation include: Placebo (DRUG), NOE-105 (DRUG).
Who is sponsoring clinical trial NCT05583955?
This trial is sponsored by Noema Pharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.